{"id":1643,"date":"2022-10-27T11:45:36","date_gmt":"2022-10-27T09:45:36","guid":{"rendered":"https:\/\/dextechmedical.com\/?p=1643"},"modified":"2022-10-27T11:32:40","modified_gmt":"2022-10-27T09:32:40","slug":"interim-report-july-1-september-30-2022","status":"publish","type":"post","link":"https:\/\/dextechmedical.com\/en\/interim-report-july-1-september-30-2022\/","title":{"rendered":"Interim report July 1 &#8211; September 30, 2022"},"content":{"rendered":"<div class=\"page\" title=\"Page 1\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p><strong>Summary of the first quarter (2022-07-01 \u2013 2022-09-30)<\/strong><\/p>\n<ul>\n<li>Net sales amounted to MSEK 0,0 (0,0)<\/li>\n<li>Operating profit\/loss amounted to MSEK -0,8 (-0,9)<\/li>\n<li>Earnings per share* SEK -0,04 (-0.06)<\/li>\n<li>Cash and cash equivalents at the end of the period amounted to MSEK 33,9 (35,5)<\/li>\n<\/ul>\n<p>* Before and after dilution. Earnings per share: Profit for the period divided by the average number of shares 18,485,857. For the comparison period, the average number of shares was 14,920,478. Amounts in brackets refer to the corresponding period last year.<\/p>\n<p><strong>CEO&#8217;s comment<\/strong><\/p>\n<p>The application for a phase 1 clinical study regarding OsteoDex treatment of multiple myeloma, has now been approved by the Swedish Medical Products Agency and permission was announced on August 10, 2022. The study will include 20 patients with multiple myeloma and be conducted at approximately 4\u20135 hospital centers in Sweden and the rest of the Nordic region. It is expected to start no later than Q1 2023 and is expected to be completed in Q3 2024.<\/p>\n<p>Principal investigator (PI) is Dr Katarina Uttervall, MD, PhD, Division of Hematology\/HERM, Karolinska University Hospital, Huddinge. The main blood markers will be analyzed at the Central Laboratory, Karolinska University Hospital, NKS, Solna. The patients included have relapsed\/treatment-resistant disease and have received 1\u20133 prior lines of therapy. The primary objective is to confirm safety and tolerability and as a secondary objective to determine treatment response documented by changes in the level of disease-related biomarkers. Documentation of quality of life will also be done (QoL scores).<\/p>\n<p>Anders R Holmberg<\/p>\n<p>CEO<\/p>\n<\/div>\n<p><a href=\"https:\/\/dextechmedical.com\/wp-content\/uploads\/Dextech-Interim-report-July-September-2022.pdf\">Dextech &#8211; Interim report July-September 2022<\/a><\/p>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Summary of the first quarter (2022-07-01 \u2013 2022-09-30) Net sales amounted to MSEK 0,0 (0,0) Operating profit\/loss amounted to MSEK -0,8 (-0,9) Earnings per share* SEK -0,04 (-0.06) Cash and [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[3],"tags":[],"class_list":["post-1643","post","type-post","status-publish","format-standard","hentry","category-okategoriserade-en"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Interim report July 1 - September 30, 2022 | DexTech<\/title>\n<meta name=\"description\" content=\"Summary of the first quarter (2022-07-01 \u2013 2022-09-30) Net sales amounted to MSEK 0,0 (0,0) Operating profit\/loss amounted to MSEK -0,8 (-0,9) Earnings\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/dextechmedical.com\/delarsrapport-1-juli-2022-30-september-2022\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Interim report July 1 - September 30, 2022 | DexTech\" \/>\n<meta property=\"og:description\" content=\"Summary of the first quarter (2022-07-01 \u2013 2022-09-30) Net sales amounted to MSEK 0,0 (0,0) Operating profit\/loss amounted to MSEK -0,8 (-0,9) Earnings\" \/>\n<meta property=\"og:url\" content=\"https:\/\/dextechmedical.com\/delarsrapport-1-juli-2022-30-september-2022\/\" \/>\n<meta property=\"og:site_name\" content=\"DexTech\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-27T09:45:36+00:00\" \/>\n<meta name=\"author\" content=\"G\u00f6sta Lundgren\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"G\u00f6sta Lundgren\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/dextechmedical.com\/delarsrapport-1-juli-2022-30-september-2022\/\",\"url\":\"https:\/\/dextechmedical.com\/delarsrapport-1-juli-2022-30-september-2022\/\",\"name\":\"Interim report July 1 - September 30, 2022 | DexTech\",\"isPartOf\":{\"@id\":\"https:\/\/dextechmedical.com\/#website\"},\"datePublished\":\"2022-10-27T09:45:36+00:00\",\"author\":{\"@id\":\"https:\/\/dextechmedical.com\/#\/schema\/person\/7d6388cae097fcab5953ef5d1733040c\"},\"description\":\"Summary of the first quarter (2022-07-01 \u2013 2022-09-30) Net sales amounted to MSEK 0,0 (0,0) Operating profit\/loss amounted to MSEK -0,8 (-0,9) Earnings\",\"breadcrumb\":{\"@id\":\"https:\/\/dextechmedical.com\/delarsrapport-1-juli-2022-30-september-2022\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/dextechmedical.com\/delarsrapport-1-juli-2022-30-september-2022\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/dextechmedical.com\/delarsrapport-1-juli-2022-30-september-2022\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/dextechmedical.com\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Interim report July 1 &#8211; September 30, 2022\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/dextechmedical.com\/#website\",\"url\":\"https:\/\/dextechmedical.com\/\",\"name\":\"DexTech\",\"description\":\"Ett svenskt forskningsf\u00f6retag specialiserat p\u00e5 urologisk onkologi fr\u00e4mst prostatacancer\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/dextechmedical.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/dextechmedical.com\/#\/schema\/person\/7d6388cae097fcab5953ef5d1733040c\",\"name\":\"G\u00f6sta Lundgren\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/dextechmedical.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/5e00bd305cedebf5b9069290209926ac27dd0b062e7cdfd04870526f70b02470?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/5e00bd305cedebf5b9069290209926ac27dd0b062e7cdfd04870526f70b02470?s=96&d=mm&r=g\",\"caption\":\"G\u00f6sta Lundgren\"},\"sameAs\":[\"https:\/\/dextechmedical.com\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Interim report July 1 - September 30, 2022 | DexTech","description":"Summary of the first quarter (2022-07-01 \u2013 2022-09-30) Net sales amounted to MSEK 0,0 (0,0) Operating profit\/loss amounted to MSEK -0,8 (-0,9) Earnings","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/dextechmedical.com\/delarsrapport-1-juli-2022-30-september-2022\/","og_locale":"en_US","og_type":"article","og_title":"Interim report July 1 - September 30, 2022 | DexTech","og_description":"Summary of the first quarter (2022-07-01 \u2013 2022-09-30) Net sales amounted to MSEK 0,0 (0,0) Operating profit\/loss amounted to MSEK -0,8 (-0,9) Earnings","og_url":"https:\/\/dextechmedical.com\/delarsrapport-1-juli-2022-30-september-2022\/","og_site_name":"DexTech","article_published_time":"2022-10-27T09:45:36+00:00","author":"G\u00f6sta Lundgren","twitter_misc":{"Written by":"G\u00f6sta Lundgren","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/dextechmedical.com\/delarsrapport-1-juli-2022-30-september-2022\/","url":"https:\/\/dextechmedical.com\/delarsrapport-1-juli-2022-30-september-2022\/","name":"Interim report July 1 - September 30, 2022 | DexTech","isPartOf":{"@id":"https:\/\/dextechmedical.com\/#website"},"datePublished":"2022-10-27T09:45:36+00:00","author":{"@id":"https:\/\/dextechmedical.com\/#\/schema\/person\/7d6388cae097fcab5953ef5d1733040c"},"description":"Summary of the first quarter (2022-07-01 \u2013 2022-09-30) Net sales amounted to MSEK 0,0 (0,0) Operating profit\/loss amounted to MSEK -0,8 (-0,9) Earnings","breadcrumb":{"@id":"https:\/\/dextechmedical.com\/delarsrapport-1-juli-2022-30-september-2022\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/dextechmedical.com\/delarsrapport-1-juli-2022-30-september-2022\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/dextechmedical.com\/delarsrapport-1-juli-2022-30-september-2022\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/dextechmedical.com\/en\/"},{"@type":"ListItem","position":2,"name":"Interim report July 1 &#8211; September 30, 2022"}]},{"@type":"WebSite","@id":"https:\/\/dextechmedical.com\/#website","url":"https:\/\/dextechmedical.com\/","name":"DexTech","description":"Ett svenskt forskningsf\u00f6retag specialiserat p\u00e5 urologisk onkologi fr\u00e4mst prostatacancer","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/dextechmedical.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/dextechmedical.com\/#\/schema\/person\/7d6388cae097fcab5953ef5d1733040c","name":"G\u00f6sta Lundgren","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/dextechmedical.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/5e00bd305cedebf5b9069290209926ac27dd0b062e7cdfd04870526f70b02470?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/5e00bd305cedebf5b9069290209926ac27dd0b062e7cdfd04870526f70b02470?s=96&d=mm&r=g","caption":"G\u00f6sta Lundgren"},"sameAs":["https:\/\/dextechmedical.com"]}]}},"_links":{"self":[{"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/posts\/1643","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/comments?post=1643"}],"version-history":[{"count":2,"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/posts\/1643\/revisions"}],"predecessor-version":[{"id":1647,"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/posts\/1643\/revisions\/1647"}],"wp:attachment":[{"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/media?parent=1643"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/categories?post=1643"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dextechmedical.com\/en\/wp-json\/wp\/v2\/tags?post=1643"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}